Rivaroxaban CAS 366789-02-8 Mimo>99.5% (HPLC) API Didara Giga
Ipese Olupese Rivaroxaban Awọn agbedemeji ibatan:
(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0
4- (4-Aminophenyl)morpholin-3-ọkan CAS 438056-69-0
Rivaroxaban Intermediate CAS 446292-07-5
5-Chlorothiophene-2-Carboxylic Acid CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8
Orukọ Kemikali | Rivaroxaban |
Awọn itumọ ọrọ sisọ | (S) -Rivaroxaban;(S) -5-Chloro-N- ((2-oxo-3-- (4- (3-oxomorpholino) phenyl) -oxazolidin-5-yl) methyl) thiophene-2-carbox;BAY 59-7939 |
Nọmba CAS | 366789-02-8 |
Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu |
Ilana molikula | C19H18ClN3O5S |
Òṣuwọn Molikula | 435.88 |
Brand | Ruifu Kemikali |
Nkan | Awọn pato |
Ifarahan | Funfun tabi Fere Funfun Powder |
Idanimọ A | Gbigba infurarẹẹdi ti Rivaroxaban ni ibamu si awọn iṣedede itọkasi |
Idanimọ B | Akoko idaduro ti tente oke akọkọ ti ojutu ayẹwo ni ibamu si ti ojutu ibamu eto, bi a ti gba ni mimọ enantiomeric. |
Enantiomeric ti nw | RVX RC01: ≤0.15% |
Ọrinrin (KF) | ≤0.50% |
Sulfated Ash | ≤0.10% |
Awọn Irin Eru | ≤20ppm |
Acetic Acid | ≤5000ppm |
Awọn nkan ti o jọmọ (HPLC) | |
RVX RC02 | ≤0.15% |
RVX RC03 | ≤0.15% |
RVX RC04 | ≤0.15% |
RVX RC05 | ≤0.15% |
RVX RC06 | ≤0.15% |
RVX RC07 | ≤0.15% |
RVX RC08 | ≤0.15% |
Eyikeyi miiran Olukuluku aimọ | ≤0.10% |
Lapapọ Awọn Aimọ | <0.50% |
Awọn ojutu ti o ku (GC) | |
Ethanol | ≤5000ppm |
Toluene | ≤890ppm |
Triethylamine | ≤320ppm |
Mimọ / Analysis Ọna | > 99.5% (HPLC) (lori ipilẹ anhydrous) |
Igbeyewo Standard | Standard Enterprise |
Lilo | API;Oògùn Antithrombotic;FXa onidalẹkun |
Package: Igo, apo apamọwọ Aluminiomu, 25kg / Paali Drum, tabi gẹgẹbi ibeere alabara.
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin.
Rivaroxaban(CAS:366789-02-8) (Xarelto, Bayer) jẹ oogun apakokoro ẹnu.O jẹ ifosiwewe taara ti nṣiṣe lọwọ ẹnu Xa inhibitor.Rivaroxaban jẹ itọkasi fun 'itọju ti iṣọn-ẹjẹ iṣọn jinlẹ ati iṣọn ẹdọforo, ati idena ti iṣọn-ẹjẹ iṣan jinlẹ loorekoore ati iṣọn ẹdọforo ninu awọn agbalagba'.Fun itọju ibẹrẹ ti iṣọn-ẹjẹ ẹdọforo nla, iwọn lilo iṣeduro ti rivaroxaban jẹ 15 miligiramu lẹmeji lojumọ fun awọn ọjọ 21 akọkọ ti o tẹle 20 miligiramu lẹẹkan lojoojumọ fun itọju tẹsiwaju ati idena ti iṣọn-ẹjẹ iṣọn-ẹjẹ loorekoore.Ti kii-Valvular Atrial Fibrillation (NVAF) lati ṣe idiwọ ikọlu & iṣọn-ara eto.Itọju VTE nla & idena ti loorekoore VTE [fun iṣọn-ẹjẹ iṣọn jinlẹ (DVT) ati iṣan ẹdọforo (PE)].Idena awọn iṣẹlẹ thromboembolic iṣọn-ẹjẹ (VTE) ni ibadi lapapọ yiyan tabi iṣẹ abẹ rirọpo orokun (THR, TKR).